BCTG ACQUISITION CORP BCTG 深 沪
等待开盘 09-05 09:30:00 美东时间
10.20
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 10.20
- 总市值 2.18亿
- 52周最高 14.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9.83
- 委 比 0.00%
- 总股本 2137.73万
- 历史最高 14.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 9.83
- 每 手 1
- 风险率 0.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics Corp. has approved a 1:10 common share consolidation to maintain compliance with Nasdaq listing requirements. The consolidation, subject to TSX and Nasdaq approval, is expected to take effect on August 25, 2025. Post-consolidation shares will continue trading on both exchanges under their current symbols. No fractional shares will be issued; any fractions will be rounded up or canceled. Beneficial holders do not need to take...
08-21 16:00
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
BriaCell Therapeutics Corp. announced its acceptance into Memorial Sloan Kettering Cancer Center’s 2025 Therapeutics Accelerator program to accelerate the clinical development of its Bria-OTS+ immunotherapy for multiple cancers, including breast and prostate cancer. MSK’s resources will support regulatory and manufacturing efforts, with both parties expressing confidence in the therapy’s potential to advance cancer care.
08-13 11:30
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
BriaCell Therapeutics Corp. has been granted a New Zealand patent (No. 785587) for its whole-cell cancer immunotherapy technology, which focuses on selecting treatments based on HLA allele profile matching. The patent, valid until February 27, 2037, supports the company's precision medicine approach to improve cancer care outcomes. BriaCell plans to leverage this as part of its global strategy to expand its immunotherapy platform across various c...
07-30 11:30
BriaCell Therapeutics Announces Closing of $15 million Public Offering
BriaCell Therapeutics Corp. has completed a best-efforts public offering of 12 million units, raising $15 million gross proceeds. Each unit includes one common share or a pre-funded warrant and one warrant. The pre-funded warrants are exercisable at $0.001, while the warrants are exercisable at $1.50 per share for five years. The company intends to use the net proceeds for working capital, general corporate purposes, and advancing business object...
07-16 20:05
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
BriaCell Therapeutics announced updated results from its Phase 2 study in advanced metastatic breast cancer (MBC), highlighting sustained complete resolution of temporal lobe brain metastasis and ongoing tumor reduction in an orbit lesion after over 18 months of treatment. The patient, who had failed eight prior regimens, including ADC therapy, has completed 29 treatment cycles with continued therapeutic response. The results suggest Bria-IMT may...
07-10 11:30
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
BriaCell Therapeutics Corp announced sustained complete resolution of lung metastasis in a patient with HR+, HER2-negative metastatic breast cancer treated with its Bria-OTS immunotherapy. The patient, aged 78 with advanced disease, achieved 100% tumor resolution in the lung after four doses, confirmed at two, four, and six months. No treatment-limiting toxicities were observed, and the patient remains on the study with stable disease elsewhere. ...
07-09 11:30
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
BriaCell Therapeutics has expanded its pivotal Phase 3 clinical study by adding 30 satellite locations through Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven. The study now includes 58 active sites across 15 states. BriaCell aims to complete patient enrollment by late 2025 or early 2026, with potential top-line data available as early as H1-2026. The Phase 3 trial evaluates Bria-IMT plus immune checkpoint inhibitor in adv...
07-02 11:30
Unions representing 14K Disneyland workers vote to authorize a strike
Several unions representing thousands of workers at Walt Disney's (NYSE:DIS) theme parks and other properties in Southern Calif. announced on Friday that they have voted to authorize a potential strik...
2024-07-20 22:31
顶级投资人、英超热刺队老板向美国法庭认罪 涉及证券内幕交易
①86岁的乔·刘易斯周三向纽约曼哈顿法庭承认证券欺诈等一系列罪名； ②虽然理论上他最高可被判处45年有期徒刑，但考虑到认罪协商和年龄因素，最终惩罚可能会非常有限。
2024-01-25 01:25
英国身家440亿富豪在美国自首！他“热心”推荐股票，韩国女友“梭哈”就赚了570万元
一向低调、几乎谢绝媒体采访的英国亿万富翁、英超足球俱乐部托特纳姆热刺队的老板乔·刘易斯（Joe Lewis，以下简称刘易斯）的大名罕见出现在了全球媒体头条...
2023-07-30 08:27
